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Abstract
Background: Prospective studies establishing the temporal relationship between the degree of inflammation and human
influenza disease progression are scarce. To assess predictors of disease progression among patients with influenza
A(H1N1)pdm09 infection, 25 inflammatory biomarkers measured at enrollment were analyzed in two international
observational cohort studies.
Methods: Among patients with RT-PCR-confirmed influenza A(H1N1)pdm09 virus infection, odds ratios (ORs) estimated by
logistic regression were used to summarize the associations of biomarkers measured at enrollment with worsened disease
outcome or death after 14 days of follow-up for those seeking outpatient care (FLU 002) or after 60 days for those
hospitalized with influenza complications (FLU 003). Biomarkers that were significantly associated with progression in both
studies (p,0.05) or only in one (p,0.002 after Bonferroni correction) were identified.
Results: In FLU 002 28/528 (5.3%) outpatients had influenza A(H1N1)pdm09 virus infection that progressed to a study
endpoint of complications, hospitalization or death, whereas in FLU 003 28/170 (16.5%) inpatients enrolled from the general
ward and 21/39 (53.8%) inpatients enrolled directly from the ICU experienced disease progression. Higher levels of 12 of the
25 markers were significantly associated with subsequent disease progression. Of these, 7 markers (IL-6, CD163, IL-10, LBP,
IL-2, MCP-1, and IP-10), all with ORs for the 3rd versus 1st tertile of 2.5 or greater, were significant (p,0.05) in both
outpatients and inpatients. In contrast, five markers (sICAM-1, IL-8, TNF-a, D-dimer, and sVCAM-1), all with ORs for the 3rd
versus 1st tertile greater than 3.2, were significantly (p#.002) associated with disease progression among hospitalized
patients only.
Conclusions: In patients presenting with varying severities of influenza A(H1N1)pdm09 virus infection, a baseline elevation
in several biomarkers associated with inflammation, coagulation, or immune function strongly predicted a higher risk of
disease progression. It is conceivable that interventions designed to abrogate these baseline elevations might affect disease
outcome.
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Introduction
The sudden and unexpected emergence in 2009 and subsequent
rapid global spread of a novel influenza virus, A(H1N1)pdm09,
was yet another reminder of the ongoing challenges posed by this
rapidly evolving class of respiratory viruses to world health [1,2].
Both its seeming defiance early on of well-established patterns of
seasonality, initial alarming reports of its heightened virulence in
segments of the population (e.g. otherwise healthy non-elderly
adults) not necessarily conforming to conventional risk groups,
atypical clinical manifestations, and rapid emergence of
A(H1N1)pdm09 virus as the major influenza virus causing human
disease worldwide further augmented concerns about the potential
threat of this novel virus to previous gains in prevention and
management of this respiratory infection [3]. These concerns
galvanized a global effort both to study and control
A(H1N1)pdm09 virus infection through new and heightened
surveillance, improved international communication, as well as the
rapid development, testing, and deployment of vaccine strategies
effective against the novel virus [4-6]. Fortunately, whether as a
direct major consequence of these efforts alone or perhaps more as
a combination of these efforts with still poorly understood elements
of the biology of the virus itself, influenza A(H1N1)pdm09 virus
has remained a major circulating human influenza virus but failed
to reach the heights of morbidity and mortality previously feared.
While largely still retaining its sensitivity to neuraminidase
inhibitors, along the way it also assumed a more typical seasonal
pattern of incidence and currently is considered a seasonal subtype
of H1N1 [7]. Although recently supplanted as the predominant
circulating virus in many parts of the Northern and Southern
Hemispheres by influenza A (H3N2) as well as influenza B,
A(H1N1)pdm09 remained detectable throughout 2011 influenza
and 2012.
There has been a long-standing effort to identify and better
characterize possible predictors of the severity of influenza virus
infection in the human host [8]. In particular, it would be highly
desirable for the treating clinician to have at hand a simple set of
prognostic indicators, ideally both those that are readily obtainable
from the patient and easily performed in the laboratory, that
would help to guide therapy, as well as predict which subset of
patients are potentially at greater risk for developing more serious
sequelae from influenza infection following their initial diagnosis
[9]. This is especially true if, as with A(H1N1)pdm09 virus
infection, patient characteristics and the course of infection do not
necessarily follow the typical clinical seasonal pattern for influenza.
Furthermore, such prognostic markers may provide greater insight
into which aspects of host defense are activated by the infection,
and whether this activation is beneficial or harmful to the host.
Ultimately, such insights may lead to better adjunctive therapy.
Both with A(H1N1)pdm09 virus infection and with disease due
to other seasonal influenza subtypes, considerable interest has been
generated in trying to characterize the potential role that cytokine
dysregulation (so-called ‘‘cytokine storm’’) triggered in the host
may play in the pathogenesis and outcome of the viral infection
[10]. This phenomenon includes the generation of markedly
elevated levels of various cytokines and other pro-inflammatory
mediators early in the course of natural infection that influence
both the height and duration of the innate and adaptive immune
response [11]. While overall the production of these mediators is
felt to be protective, in some cases it is possible that an exaggerated
or prolonged inflammatory response may actually contribute to a
worsened disease outcome.
The INSIGHT H1N1v Outpatient study (FLU 002) and the
INSIGHT H1N1v Hospitalization study (FLU 003) are two
international observational cohort studies of influenza launched in
2009 whose purpose is to describe adult participants in geograph-
ically diverse locations who present for medical treatment due to
influenza-like illness (ILI) and are documented to have laboratory-
confirmed influenza and their outcomes over 14 days (FLU 002)
and 60 days (FLU 003) of follow-up [12].
In this report we present the results of a comprehensive panel of
serum biomarker determinations performed on blood specimens
obtained at study entry in patients from these two cohorts with
confirmed A(H1N1)pdm09 virus infection. Our goal was to study
the association of the biomarkers with the risk of developing
worsened disease outcomes as defined a priori in the two studies.
Methods
Ethics Statement
The FLU 002 and FLU 003 protocols were approved by the
institutional review boards (IRB) or institutional ethics committees
(IEC) at the University of Minnesota and at each of the other 63
participating clinical sites worldwide. Formal written documenta-
tion of IRB/IEC approval was required of each site Principal
Investigator during the registration process that preceded site
activation as a study center. Copies of these approval letters are
filed with the central coordinating center at the University of
Minnesota. All patients gave signed informed consent prior to
enrollment.
Study Design
The two international studies, FLU 002 and FLU 003, were
initiated by the National Institutes of Health in August 2009 under
the auspices of the INSIGHT (International Network for Strategic
Initiatives in Global HIV Trials) clinical trials network. The
INSIGHT network conducts these ongoing studies through a
central coordinating center at the University of Minnesota and
four international coordinating centers located in the United
States (Washington DC), Europe (London and Copenhagen), and
Australasia (Sydney). The study design and statistical consider-
ations underlying each study were described previously [12].
Briefly, the two studies initially focused on the global manifesta-
tions of A(H1N1)pdm09 infection and together were designed to
cover a broad clinical spectrum ranging from outpatients
presenting with mild symptomatology (FLU 002) to those with
more serious disease requiring hospitalization due to complications
of influenza (FLU 003). The purpose of these studies is to estimate
the percent of adult patients presenting with influenza-like illness
(ILI) that is due to laboratory-confirmed influenza and to identify
clinical and virologic factors associated with the risk of a worsened
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disease outcome or death. Each study takes advantage of an
established international network of community and hospital-
based investigators already in place and supplemented by
additional sites seeing large numbers of adults diagnosed with
acute influenza.
Data Collection in FLU 002 and 003
At the time of enrollment the following information was
collected: patient demographics, height, weight and vital signs;
date of ILI onset, earliest contact with the health system for
current illness; use of neuraminidase inhibitors to prevent or treat
influenza in the preceding 14 days; medical history and underlying
medical conditions, pregnancy status, smoking history, and current
medications; influenza vaccination history since 2008 and
pneumococcal vaccination history; and antiviral, antibacterial
and other treatments prescribed at enrollment. Also recorded were
local laboratory test results for influenza A; chest radiograph
findings; and other local laboratory tests performed as part of
standard of care.
In both studies respiratory (nasal and oropharyngeal) swabs
were collected at enrollment and sent to one of two central
laboratories to confirm by RT-PCR the local influenza diagnosis
and to determine subtype. Identical methods were used by each
laboratory. Serum samples were also collected from each
participant at enrollment.
Patients enrolled in the outpatient study (FLU 002) with ILI
were followed for 14 days for progression to hospitalization, the
development of complications, or death. For the inpatient study
(FLU 003) patients could be enrolled while in the general ward or
in the intensive care unit (ICU). In either case patients were
followed for 60 days. For those enrolled in the general ward,
outcomes assessed included death, requirement for the ICU and/
or mechanical ventilation, or prolonged hospitalization; the latter
was defined as an inpatient stay exceeding 28 days of the 60-day
follow-up period, not necessarily consecutively. For participants
enrolled after already having been admitted to the ICU, death or
prolonged hospitalization for .28 days were the primary
outcomes.
Biomarker Study
Patients were included in this study if they had influenza
A(H1N1)pdm09 virus infection confirmed by RT-PCR at a central
laboratory and had completed ascertainment of outcome status at
day 14 and day 60 in the two studies, respectively. Serum samples
obtained at enrollment were analyzed for all such patients in the
inpatient study. For efficiency a nested case-control sampling
scheme was used in the outpatient study, where samples were
analyzed for each patient who experienced an event (28 patients)
within the 14 day follow-up period and for three controls (patients
who survived the 14 day follow-up period without complications
or hospitalization and who were declared to be symptoms-free at
day 14) matched on country of enrollment, age (6 5 years) and
duration of symptoms. For two cases only 1 suitable control and
for one case 2 controls were found (thus, a total of 79 controls
instead of 84).
The blood samples were centrifuged and stored at -80 degrees
Celsius until analysis. Sera concentrations of multiple cytokines
and chemokines were obtained using a Pro-inflammatory 9-plex
(IL-1 beta, IL-2, IL-6, IL-8, IL10, IL-12p70, GM-CSF, IFN-
gamma, and TNF-alpha), a Chemokine 9-plex (Eotaxin, MIP-
1beta, Eotaxin-3, TARC, IP-10, IL-8, MCP-1, MDC, and MCP-
4), a Vascular Injury II Panel (CRP, VCAM-1, ICAM-1, and
SAA), and LBP (Meso Scale Diagnostics, Gaithersburg, MD).
Additional ELISA results were assayed for CRP, sCD14, sCD163,
IL-6 (R&D Systems Inc., MN, USA). D-Dimer measurements
were made using the VIDAS assay system (BioMerieux, Durham,
NC). For biomarkers determined by both multiplex and ELISA,
ELISA test results are cited. IL-8 was measured using both a
chemokine and cytokine platform, only the latter was cited.
Altogether, we report the results for 25 biomarkers. The sera
samples for these studies were analyzed blinded to event status.
Samples from outpatients and hospitalized patients were analyzed
at the same time by the central laboratory at SAIC-Frederick.
While acknowledging that there is considerable overlap in
cellular origin, cascading immunological relationships, and down-
stream effects among many of these biomarkers, for ease of
comparison the 25 markers are displayed by broadly grouping
them into four functional categories: 1) macrophage pro-inflam-
matory activation response; 2) acute phase response; 3) T cell
activation response; and 4) macrophage chemokine response.
Statistical analysis
The association of each of the 25 biomarkers with disease
severity/progression was assessed in three separate analyses: 1) for
disease severity, a cross-sectional comparison of biomarker levels
for participants in FLU 002 versus FLU 003, and for those in FLU
003 enrolled in the general ward versus the ICU; 2) a comparison
of biomarker levels for participants with disease progression after
14 days of follow-up versus those without progression in FLU 002
(case-control analysis); and 3) a comparison of biomarker levels for
participants with disease progression after 60 days of follow-up
versus those without progression in FLU 003 (cohort analysis).
While power is greater for the cross-sectional comparisons than
the follow-up comparisons within each study, a disadvantage of
these comparisons is that the temporal association between the
biomarker level and disease severity is not known (i.e., whether the
biomarker is elevated as a consequence of disease severity or
predicts disease progression is uncertain). This problem is
overcome, at least in part, with the follow-up comparisons since
in both FLU 002 and FLU 003 biomarker levels were determined
prior to the disease progression outcome.
Simple summary statistics were use to describe the character-
istics of patients in the two biomarker studies. To reduce the
impact of outlying levels and to account for the positively skewed
distribution of the biomarkers, results are categorized in tertiles
and log10 transformed. The tertiles are defined separately for FLU
002 and FLU 003 [Table S1 in Supporting Information].
For the cross-sectional comparison, analysis of covariance with
covariates corresponding to age and geographic location was used
to compare the biomarker levels for patients in the two studies at
the time of enrollment. Unlike the follow-up analyses within each
study that are described below, we did not adjust for duration of
symptoms as we considered it to be on the causal pathway for this
cross-sectional comparison. For these comparisons, back-trans-
formed levels (geometric means) are cited for each study. In FLU
003, further comparisons are made for the subgroups defined by
location of enrollment (general ward versus ICU). For FLU 002,
the log10 transformed biomarker levels for the controls and events
were weighted to account for the larger FLU 002 group of patients
from which the controls were selected for biomarker analyses.
For the follow-up comparisons in FLU 002 and FLU 003,
logistic regression was used to summarize the association of each
biomarker with the disease progression outcomes. For FLU 002
conditional logistic regression analyses for matched case–control
studies were used. For FLU 003, unconditional logistic regression
analyses stratified by location of enrollment (general ward versus
ICU) and with covariates corresponding to the matching factors
used in FLU 002 (age, duration of symptoms and geographic
Serum Biomarkers and A(H1N1)pdm09 Influenza
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e57121
location) were carried out. Odds ratios (ORs) for the upper tertile
versus the lowest tertile are cited along with 95% confidence
intervals (CIs) and p-values. Analyses that used the log10
transformed biomarkers were also carried out; in the summary
tables we refer to the p-values from this analysis as the p-value for
linear trend. Analyses that further adjusted for race (black vs non-
black), gender, current smoking, BMI and history of chronic
conditions were also carried out and gave similar results. Kaplan-
Meier survival curves are used to compare the patterns of
mortality for tertiles of IL-6 in the FLU 003 study.
Two approaches were taken to minimize the risk of identifying
false-positive associations between biomarkers and disease pro-
gression by highlighting subsets of individual biomarkers: 1)
biomarkers that are significantly (p,0.05) related to disease
progression based on the linear trend p-value in both studies; and
2) biomarkers which are significant (p# 0.002) in one study but
not the other. The latter level of significance corresponds to a
Bonferroni adjusted p-value (0.05/25).
To determine the relationship of multiple biomarkers with
disease progression, we took advantage of the functional groupings
that were identified. A global test procedure proposed by O’Brien
for multiple endpoints is used [13]. With this approach, each
marker in the raw scale within a functional grouping is ranked
from lowest to highest, the ranks of the individual markers are
summed for each patient. We refer to the sum of the ranks as the
‘‘biomarker score’’. This biomarker score is then compared for
patients who experienced an event versus those who did not with
logistic regression models as described above (i.e., ORs for upper
versus lowest tertile of the biomarker score are cited). Advantages
of this procedure are simplicity and increased power if the
biomarkers within a category all trend in the same direction. A
disadvantage is that while the global test identifies biomarker
groupings that are significant, it does not provide information on
Figure 1. Biomarker study designs. The respective study designs
and distribution of patients with and without severe disease outcomes
in the outpatient case-control study FLU 002 (A) and in the
hospitalization cohort study FLU 003 (B).
doi:10.1371/journal.pone.0057121.g001
Table 1. Baseline Characteristics of the FLU 002 and FLU 003 Cohorts: Patients with Central Laboratory Confirmed A(H1N1)pdm09
Infection.
FLU 002 FLU 003
Entire Cohort Case-Control Entire Cohort General Ward ICU
No. Patients 528 107 209 170 39
Characteristics
Age – median (IQR) 30 (24, 40) 30 (25, 40) 49 (37, 61) 48 (37, 61) 51 (38, 59)
Female - % 51.5 56.1 47.8 52.9 25.6
Black race - % 6.1 8.4 4.3 4.1 5.1
BMI . 30 - % 6.4 12.9 23.0 23.8 19.4
Smoker - % 21.2 24.3 31.2 33.7 19.4
Pregnant* - % 1.8 5.0 15.7 17.0 0
Duration of symptoms – median days (IQR) 2 (1, 3) 2 (1, 3) 5 (3, 8) 5 (3, 7) 8 (5, 10)
2+ qualifying complications - % N/A N/A 34.0 29.4 53.8
Asthma or COPD - % 6.6 7.5 25.8 29.4 10.3
CVD, diabetes, liver or renal disease - % 1.9 0.9 26.8 24.7 35.9
HIV - % 7.8 11.2 3.3 2.9 5.1
Other immunosuppressive disease - % 0.8 0.9 9.6 9.4 10.3
Corticosteroids used to treat ILI - % N/A N/A 23.9 20.6 38.5
Taking statin - % 3.9 2.9 11.4 12.1 8.1
Took antiviral med w/in 14 days before enrollment - % 2.6 3.7 66.8 63.5 81.6
*Current or within past 2 weeks, among women aged # 45 years.
doi:10.1371/journal.pone.0057121.t001
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which markers are driving the statistical significance. Also, it is not
an optimal test procedure if the association of some markers with
disease outcome is positive and that of some other markers is
negative. Thus, we also carried out a likelihood ratio test that
tested the significance of adding all the markers (in the log10 scale)
in a functional category to a base model that only included age,
duration of symptoms and geographic region.
Statistical analyses were performed using SAS (Version 9.2).
Results
At the time of this biomarker investigation, 737 patients with
influenza A(H1N1)pdm09 virus infection centrally confirmed by
RT-PCR had completed ascertainment of outcome status in FLU
002 (528 patients) or FLU 003 (209 patients). Patients were
enrolled from 63 sites in 14 countries. The risk of serious outcomes
and the baseline characteristics varied considerably for partici-
pants in FLU 002 and FLU 003. Of the 528 patients with ILI seen
at one of the outpatient clinics, 28 (5.3%) had disease progression
requiring hospitalization (26 patients), one developed a severe
complication (chronic obstructive pulmonary disease exacerba-
tion), and one died within 14 days of enrollment (Figure 1A).
These 528 patients were enrolled during two influenza seasons
beginning in September 2009 in the Northern (n= 505) and
Southern (n= 23) Hemispheres.
Of the 209 hospitalized patients enrolled in FLU 003, 170 had
been enrolled while in the general ward and 39 from the ICU.
These 209 patients were also enrolled during the same two
influenza seasons in the Northern (n= 203) and Southern
Hemispheres (n = 6). Overall, during the 60-day follow-up period,
49 (23.4%) of the 209 patients died, entered the ICU (if enrolled in
the general ward), or had a hospital stay . 28 days. Figure 1B
depicts these outcomes depending on whether patients were
enrolled from the general hospital ward or from the ICU.
Table 1 summarizes the characteristics at study entry for
participants enrolled in either FLU 002 or FLU 003 overall and,
for FLU 003 participants, by location of enrollment (general ward
or ICU). As expected, the median patient age of 30 years for the
outpatient cohort was substantially lower than that of the
hospitalized cohort, as was the duration of symptoms, the
percentages of patients with an elevated BMI, who were pregnant,
who had chronic medical co-morbidities, or who had received
antiviral medication in the 14 day period prior to enrollment.
Cross-Sectional Relationship of Individual Biomarkers
with Disease Severity
Geometric means for each of the 25 biomarkers were compared
for outpatients in FLU 002 and inpatients in FLU 003 (overall and
according to location of enrollment) [Table 2]. There was a strong
correlation between levels of the individual biomarkers and the
likely severity of illness of each cohort at time of enrollment: that is,
most biomarkers were significantly lower in FLU 002 patients
compared to FLU 003 patients and, among FLU 003 patients,
biomarkers were generally lower in those enrolled while in the
general ward as compared to the ICU. Three exceptions were
IFN-c, MDC and TARC for which the means were significantly
higher for patients in FLU 002 compared to FLU 003 and for
which levels were higher for patients in FLU 003 who were
enrolled in the general hospital ward compared to the ICU. The
mean level of IP-10 was also significantly higher in patients in FLU
002 compared to the overall mean level in FLU 003 patients,
although higher in the ICU subcohort of the latter population.
Relationship of Individual Biomarkers with Disease
Progression during Follow-up
Table 3 compares characteristics for patients in each study who
had disease progression with those who did not. In FLU 002 there
was a trend for more cases than controls to be of black race
(p = 0.06). However, none of the differences between cases and
controls reached statistical significance. In FLU 003, patients with
subsequent disease progression were more likely to have a longer
duration of clinical symptoms prior to enrollment (p = 0.02) and to
use antiviral medications in the 14 day period prior to enrollment
(p = 0.03). As expected, the most striking difference between those
who progressed and those who did not was the difference in risk
for those enrolled in the general ward versus those enrolled from
the ICU (p,0.001).
Table 2. Geometric Means of Biomarkers for Patients in FLU
002 and FLU 003.
FLU 003
FLU
002* All
General
Care ICU
P-
value**
P-
value***
Macrophage Proinflammatory Activation Response
IL-6 (pg/ml) 8.1 9.7 8.2 19.4 .09 ,.001
sICAM-1 (ng/ml) 143 229 204 380 .003 .03
CD 163 (ng/ml) 468 825 774 1089 ,.001 .004
IL-8 (pg/ml) 19.4 32.3 29.1 50.7 ,.001 .005
IL-10 (pg/ml) 13.1 16.2 14.6 24.9 .08 .009
TNF-a (pg/ml) 11.2 13.4 12.4 18.7 .002 ,.001
sCD14 (ng/ml) 2037 2395 2329 2706 .002 .05
IL-12 p70 (pg/ml) 2.83 3.44 3.49 3.24 .33 .79
IL-1b (pg/ml) 0.23 0.18 0.19 0.15 .57 .72
Acute Phase Response
CRP (mg/ml) 16.2 51.7 46.1 85.0 ,.001 .008
D-dimer (mg/ml) 0.88 1.30 1.08 2.84 ,.001 ,.001
SAA (mg/ml) 55 141 131 197 ,.001 .13
LBP (mg/ml) 13.1 19.9 17.5 34.9 ,.001 ,.001
sVCAM-1 (ng/ml) 263 410 373 619 ,.001 .002
T Cell Activation Response
GM-CSF (pg/ml) 0.6 1.5 1.2 3.1 .02 .10
IL-2 (pg/ml) 1.4 2.3 2.1 3.7 .007 .003
IFN-c (pg/ml) 6.4 1.9 2.0 1.5 ,.001 .59
Macrophage Chemokine Response
MCP-1 (pg/ml) 738 680 596 1201 .33 ,.001
MCP-4 (pg/ml) 621 592 559 760 .51 .008
IP-10 (pg/ml) 1846 1267 1155 1900 .001 .01
MIP-1b (pg/ml) 144 119 117 131 .009 .36
Eotaxin (pg/ml) 986 970 963 1005 .81 .71
Eotaxin-3 (pg/ml) 14.1 17.6 16.7 21.7 .11 .11
MDC (pg/ml) 3704 2405 2470 2140 ,.001 .16
TARC (pg/ml) 371 238 253 182 ,.001 .05
*The levels in FLU 002 were weighted to take into account sampling controls
from a cohort of 528 patients.
**ANOVA for differences in log10 biomarker, FLU 002 vs FLU 003.
***ANOVA for difference in log10 biomarker, general ward vs ICU enrollment in
FLU 003.
doi:10.1371/journal.pone.0057121.t002
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Tables 4 and 5 give median values at entry for those who
progressed and those who did not in FLU 002 and FLU 003,
respectively. Also cited are ORs for the upper versus lowest tertile
of each marker, the p-value corresponding to this comparison, and
the p-value for linear trend (from a model that includes the log-
transformed level of the biomarker). Results were similar after
further controlling for race (black vs non-black), gender, current
smoking, BMI, and history of chronic conditions (data not shown).
Higher levels of 12 markers were significantly associated with
disease progression. Seven markers were significant (p, 0.05) in
both studies: IL-6, CD163, IL-10, LBP, IL-2, MCP-1, and IP-10.
For ease of comparison, Figure 2A gives the ORs (3rd/1sttertile)
and p-values for these 7 biomarkers for each study. All of the ORs
in Figure 2A are . 2.4. Five other biomarkers were significant
(p = 0.002 or smaller) in FLU 003 and not significant (p. 0.05) in
FLU 002 (Figure 2B). Of note, for FLU 002 none of the 12
biomarkers were significant at a Bonferroni-adjusted level of
significance of 0.002 or lower with the exception of IL-6
(OR=4.4).
For inpatients (FLU 003), we also examined the relationship of
IL-6 with mortality (Figure 3). Only one death occurred among
patients in the lowest tertile (,6.4 pg/mL) at enrollment; in
contrast, for the 2nd and 3rdtertiles (6.4–17.3 and.17.3 pg/mL), 7
and 12 deaths occurred (p= 0.008 for difference in mortality
among the tertiles).
Relationship of Functional Categories of Biomarkers with
Disease Progression
Figure 4 summarizes ORs (3rd/1sttertile) for the biomarker score
for each functional grouping within each study (see Table 2 for
biomarkers included in these four groupings). For both studies the
first three functional categories showed stronger relationships
(ORs were 2.7 or greater) with disease progression than did the last
(macrophage chemokine response). In part, the weaker association
of this last category with disease progression was due to some
biomarkers in that grouping having a positive association with
disease progression and others displaying an inverse association.
To investigate this further, we carried out a logistic regression
analysis for each study in which we compared the chi-square
statistic resulting from adding the last category of biomarkers to a
model that only included age, duration of symptoms and
geographic region. For FLU 003, the last category of markers
(macrophage chemokine response) contributed significantly
(p,0.001) to model fit (data not shown) as did the first three
categories, macrophage proinflammatory activation response
(p,0.001), acute phase response (p,0.001), and T cell activation
response (p = 0.03). For FLU 002, macrophage proinflammatory
activation response (p = .003) and macrophage chemokine re-
sponse (p = .02) were significant determinants of disease progres-
sion. The other two categories were of borderline significance (p-
values = 0.06 and 0.07).
Discussion
In vitro laboratory experiments, small animal model testing, and
clinical studies of humans with acute influenza, including those
infected with A(H1N1)pdm09 virus, have revealed a number of
cytokines and other mediators that appear to play a significant role
in the initial host response to influenza virus infection. In mouse or
ferret studies experimental infections with virulent strains of
influenza A viruses have been associated with higher elevations in
Table 3. Baseline Characteristics of Patients in the FLU 002 and FLU 003 Biomarker Cohorts According to Event Status.
FLU 002 FLU 003*
Cases Controls P-value** Events No Events P-value***
No. Patients 28 103 49 160
Characteristics
Age – median (IQR) 31 (26, 45) 30 (25, 39) 0.14 50 (40, 61) 49 (35, 60) .31
Female - % 64.3 52.4 0.33 36.7 51.3 .43
Black race - % 17.9 4.9 0.06 4.1 4.4 .85
BMI . 30 - % 19.2 10.1 0.15 15.8 24.7 .30
Smoker - % 21.4 30.1 0.73 26.7 32.5 .81
Pregnant**** - % 11.1 1.9 0.53 0 17.8 .96
Duration of symptoms – median days (IQR) 2 (1, 3.5) 2 (1, 3) N/A 8 (5, 10) 5 (3, 7) .02
2+ qualifying complications - % N/A N/A N/A 46.9 30.0 .20
Asthma or COPD - % 14.3 3.9 0.19 16.3 28.8 .32
CVD, diabetes, liver or renal disease - % 3.6 0.0 0.99 36.7 23.8 .17
HIV - % 17.9 8.9 0.33 6.1 2.5 .31
Other immunosuppressive disease - % 3.6 0.0 0.99 16.3 7.5 .06
Corticosteroids used to treat ILI - % N/A N/A N/A 30.6 21.9 .64
Taking statin - % 7.1 1.0 0.18 2.2 14.0 .06
Took antiviral med w/in 14 days before enrollment - % 3.6 2.9 0.93 83.3 61.9 .03
Enrolled from the ICU - % N/A N/A N/A 42.9 11.3 ,.001
*Entire FLU003 biomarker cohort independent of site of enrollment (general ward versus ICU).
**From fitting a conditional logistic regression model.
***From fitting a logistic regression model stratified by type of unit at enrollment (general ward versus ICU).
****Current or within past 2 weeks, among women aged # 45 years.
doi:10.1371/journal.pone.0057121.t003
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select biomarkers such as IL-6, TNF-a, and IFN-a and have
usually been associated with worsened disease outcomes in those
animals [14,15]. In an influenza challenge study reported in 1998
in which normal human volunteers were experimentally infected
with a seasonal influenza A (H1N1 Texas/36/91) virus, Hayden et
al. found that both IL-6 and IFN-alpha levels in nasal lavage fluids
peaked early in the course of infection and correlated directly with
viral titers, temperature, mucus production, and symptom scores
[8]. Several other clinical studies in adults or children have been
reported by investigators in which the addition of various serum or
nasal biomarker level measurements to the standard clinical
evaluation appeared to add to the diagnostic certainty of
respiratory virus infection with seasonal influenza [16–19].
In a number of generally cross-sectional studies focusing either
partially or exclusively upon confirmed cases of A(H1N1)pdm09
virus infection in specific geographic areas, potential correlations
between various cytokine levels and disease severity have been
reported. Investigators from Mexico reported that
A(H1N1)pdm09 virus infection resulted in stronger in vitro
upregulation of IL-6, CCL3, and CXCL8 in 72-hour cell cultures
as well as elevated serum levels of IL-6, CXCL8, and certain other
cytokines in individuals infected with this subtype compared to
those with seasonal influenza virus infection [20]. In separate
publications a group in Hong Kong reported that elevated levels of
IL-6, CXCL8, CCL2, and sTNFR-1 correlated with severe cases
of A(H1N1)pdm09 virus infection overall and, in particular, with
the extent and severity of influenza-associated pneumonia [21,22].
Similar findings concerning elevated IP-10 and IL-6 levels in cases
of pediatric pneumonia were reported from Korea [23]. At least
two groups from mainland China have described similar
relationships for several of the pro-inflammatory cytokines with-
A(H1N1)pdm09 virus infection, and separate groups from Spain,
Italy, and Romania have also described correlations between
elevated levels of various cytokines such as IL-6, IL-15, and TNF-a
and the severity of disease outcomes in patients with confirmed
A(H1N1)pdm09 virus infection [24–28]. Most recently, a group
Table 4. FLU 002 Patients: Odds Ratios of Progression for the Highest Versus Lowest Tertile of Each Biomarker.
Cases Controls Odds Ratio*
Biomarker Median IQR Median IQR OR 95% CI P-value P-value**
Macrophage Proinflammatory Activation Response
IL-6 (pg/ml) 17.1 9.8, 26.1 8.1 5.1, 14.7 4.44 1.35, 14.6 .01 .002
sICAM-1 (ng/ml) 143 93, 274 159 85, 282 1.01 0.30, 3.38 .98 .70
CD 163 (ng/ml) 586 494, 893 497 387, 650 2.74 0.88, 8.53 .08 .01
IL-8 (pg/ml) 20.0 11.4, 44.6 13.9 10.0, 22.9 2.68 0.87, 8.30 .09 .08
IL-10 (pg/ml) 15.3 11.2, 29.7 10.9 7.6, 16.8 3.92 1.18, 13.0 .03 .02
TNF-a (pg/ml) 11.0 9.7, 13.8 10.3 8.3, 13.2 2.94 0.87, 9.95 .08 .29
sCD14 (ng/ml) 2520 1878, 3207 2010 1660, 2516 3.05 0.99, 9.35 .05 .08
IL-12 p70 (pg/ml) 3.49 1.57, 4.41 1.86 1.22, 4.72 2.74 0.86, 8.74 .09 .44
IL-1b (pg/ml) 0.74 0.43, 1.43 0.58 0.23, 1.03 2.83 0.84, 9.57 .09 .77
Acute Phase Response
CRP (mg/ml) 25.2 9.5, 73.7 18.9 6.2, 34.8 2.10 0.68, 6.44 .20 .12
D-dimer (mg/ml) 1.22 0.70, 1.72 0.71 0.42, 1.31 4.82 1.44, 16.2 .01 .06
SAA (mg/ml) 76 27, 202 62 25, 136 1.33 0.42, 4.23 .63 .40
LBP (mg/ml) 18.8 12.8, 32.0 12.9 8.8, 20.8 3.80 1.17, 12.4 .03 .03
sVCAM-1 (ng/ml) 258 175, 477 303 165, 525 1.03 0.32, 3.31 .96 .90
T Cell Activation Response
GM-CSF (pg/ml) 1.1 0.7, 3.1 0.9 0.3, 2.5 2.26 0.65, 7.90 .20 .30
IL-2 (pg/ml) 2.8 1.4, 4.8 1.6 1.1, 2.8 7.71 1.63, 36.5 .01 .03
IFN-c (pg/ml) 9.0 3.6, 18.9 7.7 4.3, 11.6 1.48 0.47, 4.63 .50 .14
Macrophage Chemokine Response
MCP-1 (pg/ml) 897 613, 1335 696 501, 1181 2.48 0.80, 7.62 .11 .03
MCP-4 (pg/ml) 701 429, 912 695 436, 980 0.66 0.20, 2.21 .51 .90
IP-10 (pg/ml) 3454 1981, 5496 1853 1058, 2807 4.53 1.44, 14.2 .010 .003
MIP-1b (pg/ml) 142 107, 202 132 101, 237 1.17 0.40, 3.43 .77 .36
Eotaxin (pg/ml) 922 652, 1538 1001 786, 1400 0.89 0.32, 2.47 .83 .98
Eotaxin-3 (pg/ml) 18.5 13.2, 26.8 15.3 11.4, 21.0 2.99 0.91, 9.84 .07 .06
MDC (pg/ml) 3754 2687, 4980 3389 2758, 4979 0.94 0.29, 3.03 .92 .52
TARC (pg/ml) 324 208, 460 342 221, 561 0.53 0.15, 1.80 .31 .19
No. patients 28 79
*Odds ratio & p-value for highest vs lowest tertile, from conditional logistic model with matching on age, duration of symptoms and country of enrollment.
**As above, p-value for log10-transformed biomarker.
doi:10.1371/journal.pone.0057121.t004
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from Canada has found IL-6 to be an important feature of the host
response in both humans and mice infected with A(H1N1)pdm09
virus and, in the former case, found elevated IL-6 levels to be an
important predictor of severe disease [29].
Biomarker analyses from our two large ongoing international
studies of influenza described here have strengthened and
extended these observations in important ways. A major virtue
of the present studies is that these data were collected prospectively
according to a common data-set and with defined periods of
follow-up to assess disease progression, samples have been
garnered from a relatively large number of patients living in
geographically disparate regions of the world and analyzed
through common central laboratory systems using standardized
methodologies, and both studies included enrollments of patients
with different severities of A(H1N1)pdm09 virus infection span-
ning over more than a single influenza season in those areas.
Further, the samples were collected, shipped, and processed for
analysis using identical procedures to minimize any potential
artifactual effects on serum levels of the biomarkers measured.
Even after adjustments for multiple potentially confounding
variables within each dataset according to different stringencies,
there are several biomarkers whose baseline levels appear to be
highly correlated with a worsened disease course according to the
definitions of disease progression predefined for each study.
Several could have been singled out in this context. However,
the seven markers that were significantly correlated with disease
progression in both studies were IL-6, CD163, IL-10, LBP, IL-2,
MCP-1, and IP-10, a somewhat disparate set spanning all four
functional groupings. While cross-sectional comparisons between
studies must always be interpreted with caution, for six of these
seven markers, the exception being MCP-1, the absolute levels of
each at study entry also appeared to correlate with disease severity
at time of enrollment, as reflected principally by their higher
geometric mean values in hospitalized patients versus outpatients.
Table 5. FLU 003 Patients: Odds Ratios of Progression for the Highest Versus Lowest Tertile of Each Biomarker.
Events Non-events Odds Ratio*
Biomarker Median IQR Median IQR OR 95% CI P-value P-value**
Macrophage Proinflammatory Activation Response
IL-6 (pg/ml) 22.1 13.5, 27.2 9.5 3.9, 17.8 6.14 1.86, 20.3 .003 .004
sICAM-1 (ng/ml) 513 277, 729 241 101, 375 6.00 2.02, 17.8 .001 ,.001
CD 163 (ng/ml) 1251 824, 1916 650 512, 961 5.55 2.08, 14.8 ,.001 ,.001
IL-8 (pg/ml) 52.0 24.1, 85.3 22.4 13.9, 46.6 3.97 1.44, 10.9 .008 .001
IL-10 (pg/ml) 25.0 13.0, 69.9 10.5 6.7, 21.1 7.23 2.61, 20.0 ,.001 ,.001
TNF-a (pg/ml) 15.5 13.0, 24.6 12.1 9.2, 15.7 3.92 1.29, 11.9 .02 .002
sCD14 (ng/ml) 2990 2397, 3698 2249 1761, 2995 3.36 1.30, 8.68 .01 .03
IL-12 p70 (pg/ml) 2.56 1.14, 9.09 2.77 1.58, 6.69 1.09 0.45, 2.59 .85 .65
IL-1b (pg/ml) 0.52 0.25, 1.36 0.42 0.17, 0.95 1.83 0.73, 4.55 .19 .98
Acute Phase Response
CRP (mg/ml) 124 52.2, 203 46.4 22.7, 101 3.98 1.47, 10.8 .007 .008
D-dimer (mg/ml) 3.07 1.54, 4.78 1.09 0.55, 1.86 3.21 1.21, 8.48 .02 ,.001
SAA (mg/ml) 285 95, 494 187 65, 390 1.59 0.66, 3.88 .30 .13
LBP (mg/ml) 39.9 22.6, 73.9 16.9 10.5, 30.3 4.46 1.68, 11.9 .003 .006
sVCAM-1 (ng/ml) 800 536, 1152 394 181, 650 6.69 2.26, 19.8 ,.001 ,.001
T Cell Activation Response
GM-CSF (pg/ml) 3.2 2.1, 6.3 2.4 0.9, 4.2 2.09 0.81, 5.42 .13 .06
IL-2 (pg/ml) 3.8 2.0, 7.6 1.9 1.2, 3.6 2.81 1.12, 7.08 .03 .005
IFN-c (pg/ml) 3.2 1.4, 8.7 2.6 1.1, 6.3 3.81 1.39, 10.4 .009 .35
Macrophage Chemokine Response
MCP-1 (pg/ml) 1105 579, 2498 546 363, 804 4.04 1.55, 10.5 .004 ,.001
MCP-4 (pg/ml) 550 385, 754 577 389, 886 0.48 0.18, 1.25 .13 .31
IP-10 (pg/ml) 2486 954, 7175 990 532, 1935 3.73 1.48, 9.44 .005 ,.001
MIP-1b (pg/ml) 107 81, 165 118 82, 163 0.94 0.38, 2.33 .90 .90
Eotaxin (pg/ml) 980 567, 1667 981 651, 1384 0.92 0.39, 2.16 .85 .95
Eotaxin-3 (pg/ml) 17.0 13.6, 29.7 16.1 11.1, 27.2 1.34 0.50, 3.55 .56 .13
MDC (pg/ml) 1821 1346, 2524 2525 1879, 3430 0.26 0.10, 0.71 .009 .02
TARC (pg/ml) 149 93, 245 251 139, 439 0.25 0.09, 0.72 .010 .01
No. patients 49 160
*Odds ratio & p-value for highest vs lowest tertile, adjusted for enrollment unit (ICU vs general ward), age, symptom duration, and continent of enrollment.
**P-value for log10 biomarker, adjustment as above.
doi:10.1371/journal.pone.0057121.t005
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Two notable inconsistences between the cross-sectional and
follow-up findings were the associations with IFN-cand IP-10.
Both markers were lower in the cross-sectional comparison of FLU
003 participants compared to FLU 002 participants, but within
the two studies higher, not lower, levels were associated with an
increased risk of disease progression during follow-up. The reason
for this discrepancy remains unclear at present; however, the
difference may reflect a limitation of cross-sectional comparisons
in which temporal relationships are uncertain.
As a biomarker with known involvement in the pro-inflamma-
tory cascade associated with many different types of infections, as
well as one that has featured prominently in earlier other
published analyses of the potential role of biomarkers in predicting
influenza disease outcomes, we also chose to validate the strong
Figure 2. Biomarkers significantly related to disease progression. The biomarkers found to be significantly associated with disease
progression in both studies (A) and in FLU 003 only (B) are shown. Odds ratios (3rd/1st tertile) and 95% confidence intervals are depicted.
doi:10.1371/journal.pone.0057121.g002
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Figure 3. Mortality by tertiles of IL-6 in the FLU 003 study. A Kaplan-Meier graph of cumulative mortality (%) for FLU 003 participants
according to baseline levels of IL-6 as grouped into tertiles.
doi:10.1371/journal.pone.0057121.g003
Figure 4. Relationship of functional categories of biomarkers to disease progression in FLU 002 and FLU 003. The odds ratios and 95%
confidence intervals for the risk of disease progression in FLU 002 (in blue) and FLU 003 (in red) are depicted according to four functional
categorizations of the 25 biomarkers analyzed in these two studies.
doi:10.1371/journal.pone.0057121.g004
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predictive potential of IL-6 in these two studies. For both
outpatients and those requiring hospitalization, serum IL-6 was
a strong predictor of disease progression. For the hospitalized
patients in FLU 003, those with an IL-6 level in the upper two
tertiles were also at an increased of mortality. This is similar to
prior observations a decade earlier in a small number of fatal cases
of H5N1 infection [30]. A causal explanation for this is not fully
elucidated, although animal data do support an association of
elevated levels of IL-6 production with enhanced lethality of the
infecting virus [31,32].
Although the strong statistical associations found in these two
studies between select individual biomarkers and a worsened
disease outcome are compelling, nonetheless these results present
an obvious difficulty with extrapolation to the clinical arena at the
present time. Most of the biomarkers described here are part of a
multiplex testing array generally performed in a research setting
and are not a routine part of the diagnostic work-up performed for
a typical patient presenting with signs and symptoms of acute
influenza. Hence, at present they may be of more value in
providing insight into potential mechanisms of viral pathogenesis
and host defense rather than in offering direct clinical benefit.
There are some potential exceptions to this. D-dimer and CRP
assays, for example, are generally available today in most acute
care facilities as indicators of recent thrombotic events and
abnormal systemic inflammation, respectively, and the test results
are generally available in real time.
It is fair to say that, at present, there does not appear to be a
single discrete biomarker readily available to the physician at the
time of presentation that one can conclude adds unequivocably to
the ability of the standard diagnostic assessment to predict the
likelihood of disease progression in all patients. Nonetheless, as
these multiplex assays become cheaper and more readily available
beyond the research setting, this situation may improve. For
example, assuming an exaggerated or dysfunctional cytokine
response to acute influenza may actually contribute to disease
severity in some cases, their additional value may be in pinpointing
areas of this response that may be amenable to dampening or
other forms of therapeutic intervention. Thus, at the same time
that one is treating the virus in at-risk individuals, it is conceivable
that adjunctive therapy directed at abrogating or redirecting an
overly exuberant host response could also be introduced to further
improve prognosis.
Although this leap from the research setting to the bedside still
remains a challenge for the reasons cited, it is still reasonable to ask
whether in the future even stronger prognostic utility or power
might be found in analyzing select combinations or subsets of these
markers, whether identified through statistical modeling or de novo
as biologically plausible groupings. In addition to allowing for
more intelligent utilization of available biomarkers, such an
approach might further minimize justifiable concerns over
potential over-interpretation of statistical associations seen in
comparatively large batteries of single assay results not adjusted for
multiple comparisons, such as those generated by the multiplex
platforms in increasingly common use. In a limited look at this
possibility, we found that combinations of multiple biomarkers
from even four relatively indiscrete functional groupings did
generate odds ratios for disease outcomes that were statistically
robust, generalizable across both studies, and comparable to the
most potent of the single biomarkers studied. The fact that
elevated levels of certain biomarkers were found in each of the four
groupings suggests a very broad and diverse immunologic response
to acute influenza. But with further dissection of specific categories
of markers it may be possible to delineate more precisely what role
the disparate portions of the host response play in modulating the
course of infection. Whether with further exposition such a
combination approach might prove to be either more powerful or,
ideally, disease-specific than any of the single biomarkers
highlighted remains yet to be determined. In any case, these
preliminary results are intriguing and provide a rationale for
performing more detailed analyses of these particular biomarkers
as additional patients are accrued in these studies and additional
progression events recorded. It is certainly possible, for example,
that combinations of other biomarkers, or even different logical
groupings of the same biomarkers into other categories based upon
such factors as common cellular origin or relative positioning
within the pro-inflammatory cascade, might offer results of equal
or superior prognostic value or provide even greater insight into
potentially deleterious aspects of the host immune response.
The focus of this present analysis has been on the prognostic
value of baseline biomarkers in predicting the subsequent course of
disease specifically in A(H1N1)pdm09 virus-infected patients.
Since both studies are ongoing on a multi-year basis in both the
Northern and Southern Hemispheres, have been broadened to
include patients presenting with all major subtypes of seasonal
virus in circulation at the time, and now collect serial blood
specimens for up to 60 days following enrollment, the intention is
that these analyses can be expanded in at least two ways. One goal
will be to map the kinetics in serum and plasma of each of the
major biomarkers, singly and in groupings, from baseline through
the course of acute infection and until the time of resolution and
recovery. Surprisingly little is known about how these markers
change differentially over time according to such factors as disease
severity or the host’s baseline immune status, or how quickly they
return to the pre-infection state. A second goal will be to compare
the prognostic value of biomarkers in infection due to
A(H1N1)pdm09 virus to that found in infection with other
influenza viruses. It is unclear at present whether these correlations
observed with A(H1N1)pdm09 virus infection reflect broad-based
host response pathways that can be applied, for example,
universally to influenza A virus infections as a whole, or whether
more discrete differences in various cytokine response patterns will
emerge as different subtypes are examined further. These and
other types of analyses should be readily possible under the bounds
of these ongoing studies.
Supporting Information
Table S1 * The upper and lower tertiles for each of the
biomarkers are defined separately for the FLU 002 and
FLU 003 cohorts; these biomarkers are shown grouped
into the four functional categories as defined in the main
manuscript.
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